
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2739622/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nature Genetics, 2007, 39, 168-177.	21.4	1,045
2	Changes in the balance between motor cortical excitation and inhibition in focal, task specific dystonia Journal of Neurology, Neurosurgery and Psychiatry, 1995, 59, 493-498.	1.9	533
3	Changes in excitability of motor cortical circuitry in patients with parkinson's disease. Annals of Neurology, 1995, 37, 181-188.	5.3	524
4	Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. Archives of Neurology, 2010, 67, 1473.	4.5	376
5	The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain, 1998, 121, 589-600.	7.6	316
6	Retinal nerve fiber layer thinning in Parkinson disease. Vision Research, 2004, 44, 2793-2797.	1.4	310
7	Advantages of virtual reality in the rehabilitation of balance and gait. Neurology, 2018, 90, 1017-1025.	1.1	199
8	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.8	166
9	Auditory hallucinations in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 533-535.	1.9	159
10	Identification of Alzheimer disease-associated variants in genes that regulate retromer function. Neurobiology of Aging, 2012, 33, 2231.e15-2231.e30.	3.1	135
11	Kinematic analysis of upper limb trajectories in Parkinson's disease. Experimental Neurology, 1992, 118, 215-226.	4.1	124
12	Clinicogenetic study of mutations inLRRK2 exon 41 in Parkinson's disease patients from 18 countries. Movement Disorders, 2006, 21, 1102-1108.	3.9	113
13	Are Parkinson disease patients protected from some but not all cancers?. Neurology, 2007, 69, 1542-1550.	1.1	112
14	EEG in demented and non-demented parkinsonian patients. Acta Neurologica Scandinavica, 1988, 78, 1-5.	2.1	104
15	Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology, 1996, 47, 785-788.	1.1	78
16	Selective impairment of prediction error signaling in human dorsolateral but not ventral striatum in Parkinson's disease patients: evidence from a model-based fMRI study. NeuroImage, 2010, 49, 772-781.	4.2	78
17	Self-selected gait speed - over ground versus self-paced treadmill walking, a solution for a paradox. Journal of NeuroEngineering and Rehabilitation, 2015, 12, 20.	4.6	77
18	Higher Frequency of Certain Cancers in <i>LRRK2</i> G2019S Mutation Carriers With Parkinson Disease. JAMA Neurology, 2015, 72, 58.	9.0	76

#	Article	IF	CITATIONS
19	Inspiratory Muscle Training and the Perception of Dyspnea in Parkinson's Disease. Canadian Journal of Neurological Sciences, 2005, 32, 213-217.	0.5	72
20	Association of Polymorphisms in the Angiotensin-Converting Enzyme Gene with Alzheimer Disease in an Israeli Arab Community. American Journal of Human Genetics, 2006, 78, 871-877.	6.2	69
21	Sequence Variants in SLC6A3, DRD2, and BDNF Genes and Time to Levodopa-Induced Dyskinesias in Parkinson's Disease. Journal of Molecular Neuroscience, 2014, 53, 183-188.	2.3	67
22	Association between amantadine and the onset of dementia in Parkinson's disease. Movement Disorders, 2006, 21, 1375-1379.	3.9	66
23	Lupus anticoagulant and late onset seizures. Acta Neurologica Scandinavica, 1989, 79, 114-118.	2.1	57
24	Kinematic properties of upper limb trajectories in idiopathic torsion dystonia Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 312-319.	1.9	57
25	Respiratory Muscle Performance and the Perception of Dyspnea in Parkinson's Disease. Canadian Journal of Neurological Sciences, 2002, 29, 68-72.	0.5	57
26	The awakening of artistic creativity and Parkinson's disease Behavioral Neuroscience, 2013, 127, 256-261.	1.2	57
27	Enhanced creative thinking under dopaminergic therapy in Parkinson disease. Annals of Neurology, 2014, 75, 935-942.	5.3	57
28	Impaired procedural learning in obsessive?compulsive disorder and Parkinson's disease, but not in major depressive disorder. Behavioural Brain Research, 2005, 157, 253-263.	2.2	56
29	The <i>LRRK2</i> G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology, 2012, 78, 781-786.	1.1	55
30	Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. Journal of the Neurological Sciences, 2002, 203-204, 81-84.	0.6	50
31	Hypertension Increases the Probability of Alzheimer's Disease and of Mild Cognitive Impairment in an Arab Community in Northern Israel. Neuroepidemiology, 2010, 34, 99-105.	2.3	50
32	Advanced virtual reality-based rehabilitation of balance and gait in clinical practice. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231986837.	2.5	50
33	<i>Parkin</i> gene causing benign autosomal recessive juvenile parkinsonism. Neurology, 2001, 56, 1573-1575.	1.1	49
34	Camptocormia, axial dystonia, and parkinsonism: Phenotypic heterogeneity of a <i>parkin</i> mutation. Neurology, 2003, 60, 1393-1394.	1.1	49
35	High Prevalence of Mild Cognitive Impairment and Alzheimer's Disease in Arabic Villages in Northern Israel: Impact of Gender and Education. Journal of Alzheimer's Disease, 2012, 29, 431-439.	2.6	47
36	Essential tremor prevalence is low in Arabic villages in Israel. Journal of Neurology, 2006, 253, 1557-1560.	3.6	46

#	Article	IF	CITATIONS
37	Identification of Novel Candidate Genes for Alzheimer's Disease by Autozygosity Mapping using Genome Wide SNP Data. Journal of Alzheimer's Disease, 2011, 23, 349-359.	2.6	46
38	Basal Ganglia Lacunes and Parkinsonism. Neuroepidemiology, 1994, 13, 108-112.	2.3	45
39	Benign hereditary chorea: An update. Parkinsonism and Related Disorders, 2011, 17, 301-307.	2.2	45
40	Kinematic properties of upper-limb trajectories in Parkinson's disease and idiopathic torsion dystonia. Advances in Neurology, 1990, 53, 183-9.	0.8	44
41	Apolipoprotein E4 in Parkinson Disease and Dementia. Alzheimer Disease and Associated Disorders, 1998, 12, 45-48.	1.3	43
42	Cabergoline, Pramipexole and Ropinirole Used as Monotherapy in Early Parkinson???s Disease. Drugs and Aging, 2003, 20, 847-855.	2.7	43
43	Psychosis, short stature in benign hereditary chorea: A novel thyroid transcription factorâ€∃ mutation. Movement Disorders, 2008, 23, 1744-1747.	3.9	43
44	Autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: Mutation of <i>Parkin gene</i> . Neurology, 1999, 53, 1602-1602.	1.1	41
45	Visuo-Motor Coordination Deficits and Motor Impairments in Parkinson's Disease. PLoS ONE, 2008, 3, e3663.	2.5	40
46	Education effects on cognitive function in a healthy aged Arab population. International Psychogeriatrics, 2007, 19, 593-603.	1.0	39
47	Parkinsonism in adult-onset GM2 gangliosidosis. Movement Disorders, 1994, 9, 375-377.	3.9	36
48	Association between family history of dementia and hallucinations in Parkinson disease. Neurology, 2005, 64, 1712-1715.	1.1	36
49	The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 1053-1056.	2.2	33
50	Prayer at Midlife is Associated with Reduced Risk of Cognitive Decline in Arabic Women. Current Alzheimer Research, 2013, 10, 340-346.	1.4	33
51	Cutaneous malignant melanoma and Parkinson disease: Common pathways?. Annals of Neurology, 2016, 80, 811-820.	5.3	32
52	Dyskinesias in patients with Parkinson's disease: Effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. Parkinsonism and Related Disorders, 2012, 18, 1039-1041.	2.2	31
53	Mental and Motor Switching in Parkinson's Disease. Journal of Motor Behavior, 2001, 33, 377-385.	0.9	29
54	OCT and Chronic Papilledema. Ophthalmology, 2005, 112, 2238.e.	5.2	28

4

#	Article	IF	CITATIONS
55	High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. Journal of Neural Transmission, 2011, 118, 1199-1207.	2.8	28
56	Micrographia, much beyond the writer's hand. Parkinsonism and Related Disorders, 2016, 26, 1-9.	2.2	28
57	Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. Movement Disorders, 2019, 34, 1392-1398.	3.9	28
58	Genetic Movement Disorders in Patients of Jewish Ancestry. JAMA Neurology, 2014, 71, 1567.	9.0	27
59	Motor progression of Parkinson's disease with the leucineâ€rich repeat kinase 2 G2019S mutation. Movement Disorders, 2014, 29, 1057-1060.	3.9	27
60	Dopamine-transporter imaging and visuo-motor testing in essential tremor, practical possibilities for detection of early stage Parkinson's disease. Parkinsonism and Related Disorders, 2004, 10, 385-389.	2.2	26
61	The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers. Journal of Neural Transmission, 2009, 116, 1503-1507.	2.8	26
62	Alien hand sign in Creutzfeldt-Jakob disease. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 103-104.	1.9	25
63	Essential tremor might be less frequent than Parkinson's disease in North Israel Arab villages. Movement Disorders, 2009, 24, 119-122.	3.9	25
64	Motor switching abilities in Parkinson's disease and old age: temporal aspects. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 328-337.	1.9	24
65	Onset and progression of disease in familial and sporadic Parkinson's disease. American Journal of Medical Genetics Part A, 2004, 124A, 255-258.	2.4	24
66	Parkinson disease (<i>PARK</i>) genes are somatically mutated in cutaneous melanoma. Neurology: Genetics, 2016, 2, e70.	1.9	24
67	Timing and sequencing of human arm trajectories: Normal and abnormal motor behaviour. Human Movement Science, 1992, 11, 83-100.	1.4	23
68	Survival in Parkinson's disease: the effect of dementia. Parkinsonism and Related Disorders, 1998, 4, 179-181.	2.2	23
69	Coupling Between Leg Muscle Activation and EEG During Normal Walking, Intentional Stops, and Freezing of Gait in Parkinson's Disease. Frontiers in Physiology, 2019, 10, 870.	2.8	23
70	Non surgical treatment of subdural hematoma in a hemodialysis patient. Clinical Neurology and Neurosurgery, 1989, 91, 85-89.	1.4	20
71	A Comparison of Dopamine Agonists and Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease. Clinical Neuropharmacology, 2000, 23, 262-266.	0.7	20
72	Are genetic and sporadic Parkinson's disease patients equally susceptible to develop dementia?. Journal of the Neurological Sciences, 2010, 289, 23-26.	0.6	20

#	Article	IF	CITATIONS
73	Transient musical hallucinosis Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 833-833.	1.9	19
74	Persistent hemiballism in Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1013-1014.	1.9	19
75	Letters to the editor. Movement Disorders, 1996, 11, 115-116.	3.9	19
76	Acute Mania and Hemichorea. Clinical Neuropharmacology, 2001, 24, 300-303.	0.7	18
77	Excessive phase synchronization in cortical activation during locomotion in persons with Parkinson's disease. Parkinsonism and Related Disorders, 2019, 65, 210-216.	2.2	18
78	Computed tomography brain changes in Parkinsonian dementia. Neuroradiology, 1987, 29, 535-539.	2.2	16
79	Effects of Atropine on Learning and Memory Functions in Dementia. Clinical Neuropharmacology, 1990, 13, 241-247.	0.7	16
80	Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease. Movement Disorders, 1995, 10, 604-607.	3.9	16
81	Mild Cognitive Impairment is Associated with Mild Parkinsonian Signs in a Door-to-Door Study. Journal of Alzheimer's Disease, 2010, 22, 1005-1013.	2.6	16
82	Apolipoprotein E and Parkinson's disease. Annals of Neurology, 1998, 44, 294-294.	5.3	15
83	Onset age of Parkinson disease. American Journal of Medical Genetics Part A, 2002, 111, 459-460.	2.4	15
84	ARE PARKINSON DISEASE PATIENTS PROTECTED FROM SOME BUT NOT ALL CANCERS?. Neurology, 2008, 71, 1650-1651.	1.1	14
85	N30 somatosensory evoked potentials in patients with unilateral Parkinson's disease. Acta Neurologica Scandinavica, 1998, 97, 73-76.	2.1	13
86	Seeing Gravity: Gait Adaptations to Visual and Physical Inclines – A Virtual Reality Study. Frontiers in Neuroscience, 2019, 13, 1308.	2.8	13
87	Transient unilateral mydriasis as the presenting sign of aortic and carotid dissection. Neurology, 2000, 55, 1934-1935.	1.1	12
88	Do Tardive Dyskinesia and l-Dopa Induced Dyskinesia Share Common Genetic Risk Factors? An Exploratory Study. Journal of Molecular Neuroscience, 2013, 51, 380-388.	2.3	12
89	Estimating the Risk for Conversion from Mild Cognitive Impairment to Alzheimer's Disease in an Elderly Arab Community. Journal of Alzheimer's Disease, 2015, 45, 865-871.	2.6	12
90	Cerebrovascular symptoms in thromboangiitis obliterans. Acta Neurologica Scandinavica, 1989, 80, 347-350.	2.1	11

#	Article	IF	CITATIONS
91	The Melanocortin 1 Receptor (Mc1r) Variants Do Not Account for the Co-occurrence of Parkinson's Disease and Malignant Melanoma. Journal of Molecular Neuroscience, 2014, 54, 820-825.	2.3	11
92	Alzheimer's Disease and the Elderly in Israel. American Journal of Alzheimer's Disease and Other Dementias, 2015, 30, 448-453.	1.9	11
93	Intersegmental coordination patterns are differently affected in Parkinson's disease and cerebellar ataxia. Journal of Neurophysiology, 2019, 121, 672-689.	1.8	10
94	Altered Perceptual Sensitivity to Kinematic Invariants in Parkinson's Disease. PLoS ONE, 2012, 7, e30369.	2.5	10
95	Laterality of onset in idiopathic torsion dystonia. Movement Disorders, 1993, 8, 327-330.	3.9	9
96	Phenotype of the 202 adenine deletion in the <i>parkin</i> gene: 40 years of followâ€up. Movement Disorders, 2011, 26, 719-722.	3.9	8
97	Patterns of whole-body muscle activations following vertical perturbations during standing and walking. Journal of NeuroEngineering and Rehabilitation, 2021, 18, 75.	4.6	8
98	Natural Course of Idiopathic Torsion Dystonia among Jews. Neuroepidemiology, 1994, 13, 195-201.	2.3	7
99	Kufor-Rakeb Syndrome/PARK9: One Novel and One Possible Recurring Ashkenazi ATP13A2 Mutation. Journal of Parkinson's Disease, 2018, 8, 399-403.	2.8	7
100	The Lupus Anticoagulant and Dementia in Non-SLE Patients. Dementia and Geriatric Cognitive Disorders, 1992, 3, 140-145.	1.5	6
101	Subthalamic Nucleus Deep Brain Stimulation Does Not Improve Visuo-Motor Impairment in Parkinson's Disease. PLoS ONE, 2013, 8, e65270.	2.5	6
102	Re: The Apolipoprotein E ε4 Allele Increases the Risk of Drug-Induced Hallucinations in Parkinson's Disease. Clinical Neuropharmacology, 2000, 23, 230-231.	0.7	6
103	Clinical course of idiopathic torsion dystonia among Jews in Israel. Advances in Neurology, 1988, 50, 93-100.	0.8	6
104	Dystonia. Current Opinion in Neurology and Neurosurgery, 1993, 6, 350-7.	0.4	6
105	Switching abilities in Parkinson's disease. Advances in Neurology, 1996, 69, 361-9.	0.8	6
106	Healthy aging and preclinical dementia: The United States-Israel Longitudinal Database Project. , 2010, 6, 475-481.		5
107	Aggressive familial ALS with unusual brain MRI and a SOD1 gene mutation. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 228-231.	2.1	5
108	Thalamic–hypothalamic infarction presenting as first-order Horner syndrome. Journal of Neurology, 2013, 260, 1673-1674.	3.6	5

#	Article	IF	CITATIONS
109	Can we climb with our eyes? Preliminary report on the effect of conflicting virtual scenery on leveled and inclined gait. , 2013, , .		4
110	Falls in elderly people. Lancet, The, 1997, 349, 1180.	13.7	3
111	Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology, 2005, 65, 1843-1843.	1.1	3
112	Parkinson's Disease Genes Do Not Segregate with Breast Cancer Genes' Loci. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1464-1472.	2.5	3
113	Dopaminergic medication reduces interhemispheric hyper-synchronization in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 97, 39-46.	2.2	3
114	MATTERS ARISING: Inzelberg and Korczyn reply:. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 645-647.	1.9	2
115	A statistical method for quantitative evaluation of the progression of chronic diseases: the mean score graph (MSC). , 1998, 17, 2395-2403.		2
116	Exploring determinants of progression in Parkinson's disease. Is there a difference among Jewish ethnic groups?. Parkinsonism and Related Disorders, 2015, 21, 184-188.	2.2	2
117	Exploring the perceptions and stigmatizing experiences of Israeli family caregivers of people with Parkinson's disease. Journal of Aging Studies, 2021, 56, 100910.	1.4	2
118	Dominant vs. Nondominant posterior alien limb—Is it the same phenomenon?. Movement Disorders, 2008, 23, 1060-1062.	3.9	1
119	"Double crush―in Parkinson's disease. Annals of Neurology, 2010, 68, 972-972.	5.3	1
120	Cutaneous squamous cell carcinoma and the PARK2 gene. British Journal of Dermatology, 2017, 177, 323-324.	1.5	1
121	Apolipoprotein E ε4 Allele Does Not Influence the Development of Dementia in Parkinsonian Patients. Advances in Behavioral Biology, 1998, , 817-821.	0.2	1
122	Kinematic Analysis of Complex Movements in Parkinson's Disease. , 1995, , 181-187.		1
123	Dementia in non-SLE patients with lupus anticoagulant. Journal of Neuroimmunology, 1991, 35, 39.	2.3	0
124	MATTERS ARISING: Inzelberg and Korczyn reply:. Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 247-247.	1.9	0
125	Gait adaptation to conflictive visual flow in virtual environments. , 2017, , .		0
126	Gift of creativity with Parkinson's disease. BMJ: British Medical Journal, 2018, 360, k1146.	2.3	0

0

127 Current Status of Pharmacogenetics in Antithrombotic Drug Therapy. , 0, , . 0	#	Article	IF	CITATIONS
	127	Current Status of Pharmacogenetics in Antithrombotic Drug Therapy. , 0, , .		0

128 Cutaneous Manifestations of Parkinson's Disease. , 2022, , 187-198.